RESMAIN: resmonistat for CTCL maintenance

2 Views
administrator
administrator
08/09/23

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, discusses the need for improved maintenance therapies in cutaneous T-cell lymphoma (CTCL), highlighting the potential benefits of resminostat which is being explored in the RESMAIN trial (NCT02953301). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next